Saudi Oncology Society and Saudi Urology Association Combined Clinical Management Guidelines for Renal Cell Carcinoma

Overview

Journal Urol Ann

Specialty Urology

Date 2016 May 4

PMID 27141180

Citations 5

Authors

Abdullah Alghamdi

Sultan Alkhateeb

Khalid AlGhamdi

Shouki Bazarbashi

Esam Murshid

Mohammed Alotaibi

Ashraf Abusamra

Danny Rabah

Imran Ahmad

Mubarak Al-Mansour

Ahmad Saadeddin

Abdullah Alsharm

Affiliations

Soon will be listed here.

Abstract

This is an update to the previously published Saudi guidelines for the evaluation, medical, and surgical management of patients diagnosed with renal cell carcinoma (RCC). It is categorized according to the stage of the disease using the tumor node metastasis staging system 7(th) edition. The guidelines are presented with supporting evidence level, they are based on comprehensive literature review, several internationally recognized guidelines, and the collective expertise of the guidelines committee members (authors) who were selected by the Saudi Oncology Society and Saudi Urological Association. Considerations to the local availability of drugs, technology, and expertise have been regarded. These guidelines should serve as a roadmap for the urologists, oncologists, general physicians, support groups, and healthcare policy makers in the management of patients diagnosed with RCC.

Citing Articles

Saudi Urological Association consensus guidelines on the use of robotic surgery in urology.

Azhar R, Rabah D, Alenizi A, Alammari A, Alasker A, AlQahtani A Urol Ann. 2022; 14(3):199-204.

PMID: 36117790 PMC: 9472305. DOI: 10.4103/ua.ua_46_22.

Surveillance for low-risk kidney cancer: a narrative review of contemporary worldwide practices.

Cui H, Sullivan M Transl Androl Urol. 2021; 10(6):2762-2786.

PMID: 34295761 PMC: 8261444. DOI: 10.21037/tau-20-1295.

Oncology research in Saudi Arabia over a 10-year period. A synopsis.

Alghamdi M, Alzahrani R, Alhashemi H, Obaid A, Alghamdi A, Aldokhi M Saudi Med J. 2020; 41(3):261-266.

PMID: 32114598 PMC: 7841566. DOI: 10.15537/smj.2020.3.24912.

Quality assessment of kidney cancer clinical practice guidelines using AGREE II instrument: A critical review.

Hou X, Li M, He W, Wang M, Yan P, Han C Medicine (Baltimore). 2019; 98(40):e17132.

PMID: 31577704 PMC: 6783175. DOI: 10.1097/MD.0000000000017132.

Epidemiology profile of renal cell carcinoma: A 10-year patients' experience at King Abdulaziz Medical City, National Guard Health Affairs, Saudi Arabia.

Mahasin S, AlOudah N, Al-Surimi K, Alkhateeb S Urol Ann. 2018; 10(1):59-64.

PMID: 29416277 PMC: 5791459. DOI: 10.4103/UA.UA_102_17.

References

Leibovich B, Blute M, Cheville J, Lohse C, Weaver A, Zincke H . Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004; 171(3):1066-70. DOI: 10.1097/01.ju.0000113274.40885.db. View

Luo J, Zhou F, Xie D, Zhang Z, Liao B, Zhao H . Analysis of long-term survival in patients with localized renal cell carcinoma: laparoscopic versus open radical nephrectomy. World J Urol. 2009; 28(3):289-93. DOI: 10.1007/s00345-009-0487-9. View

Flanigan R, Salmon S, Blumenstein B, Bearman S, Roy V, McGrath P . Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2002; 345(23):1655-9. DOI: 10.1056/NEJMoa003013. View

Berger A, Brandina R, Atalla M, Herati A, Kamoi K, Aron M . Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol. 2009; 182(5):2172-6. DOI: 10.1016/j.juro.2009.07.047. View

OMalley R, Berger A, Kanofsky J, Phillips C, Stifelman M, Taneja S . A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. BJU Int. 2006; 99(2):395-8. DOI: 10.1111/j.1464-410X.2006.06554.x. View

Abouassaly R, Lane B, Novick A . Active surveillance of renal masses in elderly patients. J Urol. 2008; 180(2):505-8. DOI: 10.1016/j.juro.2008.04.033. View

Rais-Bahrami S, Guzzo T, Jarrett T, Kavoussi L, Allaf M . Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int. 2009; 103(10):1355-8. DOI: 10.1111/j.1464-410X.2008.08242.x. View

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View

10.

Eastham J . Do high-volume hospitals and surgeons provide better care in urologic oncology?. Urol Oncol. 2009; 27(4):417-21. DOI: 10.1016/j.urolonc.2009.01.010. View

11.

Marshall F, Taxy J, Fishman E, Chang R . The feasibility of surgical enucleation for renal cell carcinoma. J Urol. 1986; 135(2):231-4. DOI: 10.1016/s0022-5347(17)45594-7. View

12.

Simmons M, Weight C, Gill I . Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. Urology. 2009; 73(5):1077-82. DOI: 10.1016/j.urology.2008.11.059. View

13.

Weight C, Larson B, Gao T, Campbell S, Lane B, Kaouk J . Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology. 2010; 76(3):631-7. DOI: 10.1016/j.urology.2009.11.087. View

14.

Motzer R, Escudier B, Oudard S, Hutson T, Porta C, Bracarda S . Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010; 116(18):4256-65. DOI: 10.1002/cncr.25219. View

15.

Kim S, Thompson R, Boorjian S, Weight C, Han L, Murad M . Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012; 188(1):51-7. DOI: 10.1016/j.juro.2012.03.006. View

16.

Strouse J, Spevak M, Mack A, Arceci R, Small D, Loeb D . Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2004; 44(4):407-11. DOI: 10.1002/pbc.20292. View

17.

van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A . A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2010; 59(4):543-52. DOI: 10.1016/j.eururo.2010.12.013. View

18.

Gill I, Kavoussi L, Lane B, Blute M, Babineau D, Colombo Jr J . Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007; 178(1):41-6. DOI: 10.1016/j.juro.2007.03.038. View

19.

Blom J, van Poppel H, Marechal J, Jacqmin D, Schroder F, de Prijck L . Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2008; 55(1):28-34. DOI: 10.1016/j.eururo.2008.09.052. View

20.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22):2271-81. DOI: 10.1056/NEJMoa066838. View